Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 6/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13010052 | 0.94 | TYMP (0.51) | TYMPPRMT6P2RY12GAPDH | |
| SCHEMBL13010051 | 0.93 | TYMP (0.51) | TYMPP2RY12ADORA1ADORA2AADORA2B | |
| SCHEMBL17861061 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL21158665 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL19509810 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL29936775 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL21652355 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL21574271 | 0.87 | TYMP (0.54) | TYMPPRMT6P2RY12ADORA1ADORA2A | |
| SCHEMBL6894664 | 0.85 | TYMP (0.54) | TYMPP2RY12ADORA1GAPDH | |
| SCHEMBL6898807 | 0.85 | TYMP (0.55) | TYMPP2RY12ADORA1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317714-A1 | COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS | SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317714-A1 | COMPLEX MOLECULE INTERFERING THE EXPRESSION OF TARGET GENES AND ITS PREPARING METHODS | DCLRE1B, RNASE1, AGO2 | TYMP 1836/4885PRMT6 2136/4885P2RY12 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.